HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer
نویسندگان
چکیده
منابع مشابه
HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer
We have shown that WT-161, a histone deacetylase 6 (HDAC6) inhibitor, shows remarkable anti-tumor activity in multiple myeloma (MM) in preclinical models. However, its activity in other type of cancers has not yet been shown. In this study, we further evaluated the biologic sequelae of WT161 in breast cancer cell lines. WT161 triggers apoptotic cell death in MCF7, T47D, BT474, and MDA-MB231 cel...
متن کاملEpidermal Growth Factor Receptors and Breast Cancer
Growth factors are polypeptides that stimulate cell proliferation through binding to specific high-affinity cell membrane receptors. Plasma contains small quantities of growth factors. Platelets contain large amounts and it is thought that these are delivered to sites of injury where they may influence wound healing and repair. Growth factors are present in a variety of other tissues and have d...
متن کاملGrowth factor receptors in breast cancer: potential for therapeutic intervention.
Increased expression and activation of receptor tyrosine kinases occurs frequently in human breast carcinomas. Several therapies targeting these receptors are currently in clinical trials. Therapeutic strategies include blockade of individual receptors with monoclonal antibodies and inhibition of tyrosine kinase function. Trastuzumab is the first of these biologic therapies to be approved for p...
متن کاملBreast cancer and therapeutic deployment of growth factor receptors
Growth factors and their receptor play a major part in normal growth and differentiation and also in tumour development and progression. Mutations or overexpression of growth factor receptors is associated with aggressive cancers and poor prognosis for patients. Growth factor receptors are transmembrane tyrosine kinase proteins that transduce growth factor signals imparted by their binding to s...
متن کاملQuantitation of Vascular Endothelial Growth Factor and Interleukin-6 in Different Stages of Breast Cancer
Background: Determination of the impact of angiogenesis on tumor development and progression is essential. This study aimed to determine the serum levels of Vascular endothelial growth factor (VEGF) and Interleukin 6 (IL-6) in breast carcinoma, and to correlate them with tumor size, lymph node involvement, and cancer stage. Methods: Under aseptic precautions 5 ml of venous blood was collecte...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncotarget
سال: 2017
ISSN: 1949-2553
DOI: 10.18632/oncotarget.19019